ARKG stock forecast, quote, news & analysis

Key Takeaways

• ARKG has climbed roughly 18% over the trailing 30 days, extending a gain of approximately 35% over the prior three months.
• The fund is an actively managed, thematic ETF concentrated in genomics, gene editing, DNA sequencing, molecular diagnostics, and AI-enabled drug discovery.
• Top holdings including TWST, TEM, and TXG have been among the most influential contributors to the recent advance.
• The move reflects renewed risk appetite for high-growth innovation stocks and broadening momentum across precision medicine and AI-driven biotechnology.

ARK Genomic Revolution ETF (ARKG) Overview and Portfolio Exposure

The ARK Genomic Revolution ETF is an actively managed thematic exchange-traded fund (ETF) from ARK Invest. It seeks long-term growth of capital by investing primarily in companies relevant to the "genomics revolution," spanning healthcare, information technology, materials, energy, and consumer discretionary. The fund typically holds a concentrated portfolio of roughly 30 positions, with an expense ratio of 0.75%.

Exposure is overwhelmingly tilted toward healthcare, which represents close to 99% of assets, with a small allocation to information technology. As of mid-2026, the largest positions included Twist Bioscience (TWST), Tempus AI (TEM), 10x Genomics (TXG), Absci (ABSI), CRISPR Therapeutics (CRSP), Personalis (PSNL), Beam Therapeutics (BEAM), Guardant Health (GH), Natera (NTRA), and Illumina (ILMN).

Because the portfolio is concentrated in early-stage, high-growth, and often pre-profit companies, ARKG tends to exhibit elevated volatility (ETF volatility) relative to broad market benchmarks. This structure amplifies both gains and losses when sentiment toward innovation-driven healthcare shifts.

ARK Genomic Revolution ETF (ARKG) Price Performance: Last 30 Days vs. Quarter

Over the trailing 30 days, ARKG advanced from roughly $39.62 to $46.84, a gain of approximately 18%. The move was not a straight line; the fund traded lower through much of July before a sharp, momentum-driven rally began in August and carried into September.

The quarterly picture is even stronger. Three months earlier, ARKG traded near $34.75, meaning the fund has appreciated roughly 35% over the period. This places ARKG's recent price movement firmly in trend-driven territory, with periodic pullbacks followed by renewed buying rather than a slow, steady grind higher.

What Drove ARKG Price in the Last 30 Days

Several of the fund's largest and most volatile holdings were the primary engines of the recent ETF performance. Synthetic biology and sequencing names such as Twist Bioscience and 10x Genomics, alongside AI-driven precision-medicine platforms like Tempus AI, have ranked among the strongest performers in the genomics complex, directly lifting the fund's net asset value (NAV).

The broader driver has been a resurgence of investor appetite for innovation-led healthcare. Enthusiasm around artificial intelligence applied to drug discovery and diagnostics has re-rated several ARKG constituents, while gene-editing pioneers including CRISPR Therapeutics, Beam Therapeutics, and Intellia Therapeutics have benefited from continued clinical and partnership momentum. ARK Invest has also actively repositioned the fund, adding to gene-editing and sequencing exposure while trimming select diagnostics holdings.

Macroeconomic conditions reinforced the move. A more favorable interest-rate backdrop and cooling inflation expectations tend to support long-duration, high-growth equities whose valuations are most sensitive to discount rates, providing a tailwind for the fund's concentrated genomics exposure.

What Drove ARKG Performance Over the Last Quarter

The three-month advance reflects a broader sector rotation back into innovation and growth-oriented equities. As risk appetite improved, capital flowed toward thematic biotechnology and precision-medicine strategies, favoring the small- and mid-cap companies that dominate ARKG's portfolio.

Fundamentals also mattered. Several core holdings reported meaningful revenue acceleration and expanding partnerships across AI-driven drug discovery, liquid biopsy, and synthetic biology, supporting higher valuations. The fund's active-management approach allowed it to concentrate exposure in the strongest-performing segments of the genomics theme, amplifying the quarter's gains relative to more diversified healthcare benchmarks. Institutional and retail flows into thematic ETFs (exchange-traded funds) provided additional support.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery platform designed to help investors scan thousands of securities using technical indicators, fundamentals, volatility metrics, price patterns, industry filters, AI-generated signals, and performance characteristics. It helps users identify trending securities, breakout candidates, and new trading opportunities more efficiently than manual screening. By combining customizable filters with AI-driven analysis, the platform streamlines the research process for both retail and professional investors looking to evaluate ETF performance and sector exposure at scale. Explore the AI Screener to refine your market research workflow.

ARKG ETF Outlook: What Investors Should Watch Next

Going forward, investors should monitor the trajectory of interest rates and inflation, which remain key drivers of valuation for ARKG's long-duration, high-growth holdings. Any shift toward higher-for-longer rates could pressure the fund's most richly valued constituents.

Company-specific catalysts will also matter. Clinical trial readouts, regulatory decisions, and partnership announcements across gene-editing, liquid biopsy, and AI-driven drug discovery are likely to drive idiosyncratic moves in top holdings. The sustainability of revenue growth among sequencing and diagnostics leaders such as Twist Bioscience, 10x Genomics, and Tempus AI will be closely watched.

Finally, capital flows into thematic ETFs and the broader risk appetite for innovation equities will shape near-term momentum. ARKG's concentrated, high-volatility structure means that both upside and downside risk remain substantial, and the fund is likely to remain sensitive to shifts in investor sentiment around the genomics and precision-medicine investment theme.

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations